Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0193
Source ID: NCT03976115
Associated Drug: Ddo-3055
Title: A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Chronic Kidney Disease
Interventions: DRUG: DDO-3055|DRUG: Placebos
Outcome Measures: Primary: Adverse Events(AEs) and Serious Adverse Events (SAEs), Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events, from informed consent form signature to the end of the study (up to 14 days) | Secondary: Area under the plasma concentration versus time curve (AUC) of DDO-3055, Pre-dose to 72 hours after dose administration|Maximum observed serum concentration (Cmax) of DDO-3055, Pre-dose to 72 hours after dose administration|Time to maximum observed serum concentration (tmax) of DDO-3055, Pre-dose to 72 hours after dose administration|Time to elimination half-life (t1/2) of DDO-3055, Pre-dose to 72 hours after dose administration|Apparent total clearance of the drug from plasma after oral administration (CL/F) of DDO-3055, Pre-dose to 72 hours after dose administration|Apparent volume of distribution after non-intravenous administration (V/F) of DDO-3055, Pre-dose to 72 hours after dose administration|Renal clearance of the drug from plasma (CLR) of DDO-3055, Pre-dose to 72 hours after dose administration|Changes in red blood cell count relative to baseline, up to 14 days|Changes in reticulocyte count relative to baseline, up to 14 days|Changes in hemoglobin relative to baseline, up to 14 days|Changes in endogenous erythropoietin relative to baseline, up to 14 days
Sponsor/Collaborators: Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 54
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
Start Date: 2019-07-18
Completion Date: 2021-05-11
Results First Posted:
Last Update Posted: 2022-06-14
Locations: Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
URL: https://clinicaltrials.gov/show/NCT03976115